Access to Highly Purified Chondroitin Sulfate for Appropriate Treatment of Osteoarthritis: A Review
Доступность высокоочищенного хондроитина сульфата для надлежащего лечения остеоартрита: обзор
2017-01-01
SCID: 54.1/6336my64
Discuss with AI
cartilage deteriorationnutraceuticalsosteoarthritispharmaceutical-grade chondroitin sulfatesymptomatic slow-acting drugs
Figures from the paper
Abstract (AI)
Current pharmacological therapies for osteoarthritis are symptom-focused and aimed at controlling pain. However, currently approved symptom-modifying agents do not restore the structure and function of damaged joints. Symptomatic slow-acting drugs in osteoarthritis (SySADOAs), including the sulfated glycosaminoglycan, chondroitin sulfate, have shown promising beneficial effects on the pain and other symptoms of osteoarthritis, and some may also have a positive effect on cartilage, slowing the progression of joint deterioration in osteoarthritis. A highly-purified, standardized, pharmaceutical-grade preparation of chondroitin sulfate has shown activity in osteoarthritis and has become one of the most prescribed SySADOAs. However, in many countries, formulations of chondroitin sulfate of various sources and purity are available as food supplements or nutraceuticals. As the effects of chondroitin sulfate could vary according to the characteristics of the chondroitin sulfate employed, including source, purity, or structural organization, clinical data from well-designed studies of pharmaceutical-grade chondroitin sulfate should not be extrapolated to support clinical efficacy claims of food supplements; nor should results from trials of chondroitin sulfate-containing food supplements be used to draw conclusions about the efficacy of pharmaceutical-grade chondroitin sulfate. This article reviews the evidence for the role of highly-purified pharmaceutical-grade chondroitin sulfate in the treatment of osteoarthritis and examines the efficacy and safety concerns of other formulations of chondroitin sulfate. Highly-purified pharmaceutical-grade chondroitin sulfate has mild-to-moderate efficacy in the treatment of symptomatic osteoarthritis, with clinically meaningful efficacy.
Key Findings
1
Chondroitin sulfate effects may vary with source, purity, and structural organization, so evidence cannot be extrapolated between pharmaceutical-grade products and food supplements.
2
Chondroitin sulfate, a symptomatic slow-acting osteoarthritis drug, may reduce pain and other symptoms and potentially slow cartilage deterioration.
3
Clinical efficacy claims for chondroitin sulfate supplements require formulation-specific evidence, and supplement trials cannot establish the efficacy of pharmaceutical-grade chondroitin sulfate.
4
Current osteoarthritis pharmacotherapies primarily control pain and generally do not restore damaged joint structure or function.
5
Highly purified, standardized, pharmaceutical-grade chondroitin sulfate demonstrates mild-to-moderate but clinically meaningful efficacy for symptomatic osteoarthritis.
Research Object
Highly-purified pharmaceutical-grade chondroitin sulfate formulations used to treat osteoarthritis
Research Subject
The clinical efficacy and safety of chondroitin sulfate, including effects on osteoarthritis symptoms and joint deterioration, in relation to formulation source, purity, and structural organization
Publication Details
Publication Date
2017-01-01
Journal
Publisher
ISSN
Cited by
14
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai4
American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee2012
Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 20152016
An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)2014
Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT)2017